Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis.

MLA

Gambella, Manuela, et al. “Minimal Residual Disease by Flow Cytometry and Allelic-Specific Oligonucleotide Real-Time Quantitative Polymerase Chain Reaction in Patients with Myeloma Receiving Lenalidomide Maintenance: A Pooled Analysis.” Cancer (0008543X), vol. 125, no. 5, Mar. 2019, pp. 750–60. EBSCOhost, https://doi.org/10.1002/cncr.31854.

APA

Gambella, M., Omedé, P., Spada, S., Muccio, V. E., Gilestro, M., Saraci, E., Grammatico, S., Larocca, A., Conticello, C., Bernardini, A., Gamberi, B., Troia, R., Liberati, A. M., Offidani, M., Rocci, A., Palumbo, A., Cavo, M., Sonneveld, P., Boccadoro, M., & Oliva, S. (2019). Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis. Cancer (0008543X), 125(5), 750–760. https://doi.org/10.1002/cncr.31854

Chicago

Gambella, Manuela, Paola Omedé, Stefano Spada, Vittorio Emanuele Muccio, Milena Gilestro, Elona Saraci, Sara Grammatico, et al. 2019. “Minimal Residual Disease by Flow Cytometry and Allelic-Specific Oligonucleotide Real-Time Quantitative Polymerase Chain Reaction in Patients with Myeloma Receiving Lenalidomide Maintenance: A Pooled Analysis.” Cancer (0008543X) 125 (5): 750–60. doi:10.1002/cncr.31854.